Sign in to fuzzto save your conversations, follow your research and come back anytime.
Fortis Healthcare
SectorHealthcare
Fortis Healthcare Limited is one of India's largest healthcare providers, operating 27 hospitals with 4,500 operational beds and over 426 diagnostics centres as of March 31, 2023. The company offers a wide range of integrated healthcare services including cardiac care, orthopedics, neurosciences, oncology, renal care, gastroenterology, and mother and child care. Fortis uses advanced technology to deliver quality healthcare in modern facilities. Its subsidiary, SRL Limited, is a leading diagnostics chain in India. Fortis Healthcare has a presence in India, Dubai, Mauritius, and Sri Lanka. The company has expanded through acquisitions and new facility launches over the years, focusing on its core Indian market in recent times. It provides inpatient and outpatient services, sells medical and non-medical items, and offers management services to hospitals. Fortis Healthcare's specialties include cardiac sciences, cosmetology, dental sciences, dermatology, general surgery, oncology, urology, neurosurgery, radiology, orthopedics, and organ transplant.
In the news
SC questions drug price caps beyond cancer medicines, pharma stocks fall
Hospital stocks face 2-9% EBITDA hit as SC flags ₹27,000 cancer drug markup
SC allows Fortis forensic audit despite promoter debt concerns
Fortis Healthcare climbs 2.94% after ₹567 cr Delhi hospital deal
Fortis Healthcare Challenges Delhi HC Forensic Audit Order
Prabhudas Lilladher raises Fortis Healthcare target to ₹2320
Delhi HC orders 6-month forensic audit of Singh brothers' assets
Delhi Master Plan 2047 boosts Max, Fortis, Medanta stocks
Indus Towers AGM approves FY26 financials, dividend amid institutional dissent
ICICI Securities recommends Fortis Healthcare buy at ₹1075 target
Fortis Healthcare Q1 FY27 Results: Multiple Brokerages Set ₹1100-1130 Targets
Fortis Healthcare reappoints Raghuvanshi as MD for 2 years
Fortis Healthcare partners Dion Group for 300-bed Odisha hospital
Delhi CM orders strict action against Fortis Shalimar Bagh after inquiry
Religare Broking suggests 3 stock strategies amid market volatility
Q4FY26 Turnaround Tales: Five Paths to Profitability
Mirae Asset recommends sell calls on Kalyan Jewellers, IndiGo
Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results
Medical tourism recovery stalled by West Asia conflict
79 Companies Report Q4FY26 Results Today: Mixed Performance
The Quarter story
The two most recent quarterly results, compared side-by-side.
Fortis Healthcare expands revenue and patient pricing, though rising costs and margin pressure test profitability.
Consolidated revenue grows from ₹2,166.7 Cr to ₹2,545.0 Cr from Q1 FY26 to Q1 FY27 — steady top-line expansion across hospitals and diagnostics.
Operating expenses accelerate from ₹1,676.0 Cr to ₹2,007.9 Cr from Q1 FY26 to Q1 FY27 — cost inflation outpaces revenue growth.
Average realization per patient rises from ₹878 to ₹952 from Q1 FY26 to Q1 FY27 — stronger pricing power and higher-value treatments.
Consolidated EBITDA margin contracts from 22.6% to 22.3% from Q1 FY26 to Q1 FY27 — margin compression from higher operational costs.
Diagnostics operating margin expands from 23.0% to 23.9% from Q1 FY26 to Q1 FY27 — improved efficiency and a growing direct-to-consumer base.
Cash reserves fall from ₹486 Cr to ₹347 Cr from Q1 FY26 to Q1 FY27 — tighter liquidity amid capex and debt servicing.
High-performing hospital facilities grow from 11 to 14 from Q1 FY26 to Q1 FY27 — core assets scale effectively with stable occupancy.
International payor share drops from 8.1% to 7.5% from Q2 FY26 to Q1 FY27 — weaker cross-border demand pressures revenue mix.
Net debt to EBITDA improves from 0.92x to 1.01x from Q1 FY26 to Q1 FY27 — leverage remains manageable despite ongoing capital investments.
Hospital EBITDA margin declines from 22.6% to 20.6% from Q1 FY26 to Q1 FY27 — core operations face profit squeeze despite steady bed occupancy.
Company insights, generated from the most recent coverage.
Sep 30 volume of 5.2L shares was ~79% below average — thin participation suggests weak conviction buying rather than aggressive institutional distribution.
RSI at 25 is deeply oversold but ADX at 43.8 confirms a powerful downtrend — oversold alone is not a buy signal while momentum stays this strong.
SC disposal of Fortis's SLP lets the forensic audit proceed, converting a tail-risk into a live overhang that is now overriding strong operating fundamentals.